Bio-Rad Laboratories（BIO）株式概要
バイオ・ラッド・ラボラトリーズ社は、米国、ヨーロッパ、アジア、カナダ、ラテンアメリカ、そして国際的にライフサイエンス研究・臨床診断製品の開発、製造、販売を行っている。 詳細
BIO Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bio-Rad Laboratories, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$296.86 |
| 52週高値 | US$343.12 |
| 52週安値 | US$236.73 |
| ベータ | 1.08 |
| 1ヶ月の変化 | 0.86% |
| 3ヶ月変化 | 6.78% |
| 1年変化 | 20.16% |
| 3年間の変化 | -23.78% |
| 5年間の変化 | -55.95% |
| IPOからの変化 | 11,516.26% |
最新ニュース
ナラティブの更新 • Jul 02
BIO: Fair Outlook Will Balance Activist Pressure Against Refined Return Assumptions
Analysts have reduced their price target on Bio-Rad Laboratories from $325 to $275, citing updated assumptions that now reflect slightly higher discount rates, a lower revenue growth outlook, a modestly adjusted profit margin, and a recalibrated future P/E multiple. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and publicly called for steps to improve the company’s share price, citing what it described as more than a 70% decline from a peak in late 2021.
ナラティブの更新 • Jun 18
BIO: Activist Campaign And Ongoing Buybacks Will Drive Future Share Price
Analysts have kept their $320 price target on Bio-Rad Laboratories steady, citing only modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that offset each other in their valuation models. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and called for actions aimed at raising the share price, citing what it describes as more than a 70% decline from a peak in late 2021.ナラティブの更新 • Jun 04
BIO: Activist Pressure And Buybacks Will Shape Future Value Realization
Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.Recent updates
ナラティブの更新 • Jul 02
BIO: Fair Outlook Will Balance Activist Pressure Against Refined Return Assumptions
Analysts have reduced their price target on Bio-Rad Laboratories from $325 to $275, citing updated assumptions that now reflect slightly higher discount rates, a lower revenue growth outlook, a modestly adjusted profit margin, and a recalibrated future P/E multiple. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and publicly called for steps to improve the company’s share price, citing what it described as more than a 70% decline from a peak in late 2021.ナラティブの更新 • Jun 18
BIO: Activist Campaign And Ongoing Buybacks Will Drive Future Share Price
Analysts have kept their $320 price target on Bio-Rad Laboratories steady, citing only modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions that offset each other in their valuation models. What’s in the News for Bio-Rad Laboratories On May 18, 2026, Elliott Investment Management LP disclosed a significant stake in Bio-Rad Laboratories and called for actions aimed at raising the share price, citing what it describes as more than a 70% decline from a peak in late 2021.ナラティブの更新 • Jun 04
BIO: Activist Pressure And Buybacks Will Shape Future Value Realization
Analysts have reaffirmed their $320.00 price target for Bio-Rad Laboratories, citing adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the main factors behind the updated view. What's in the News Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories after the stock declined more than 70% from its late 2021 peak, and is publicly pushing for improvements in the share price and company performance.
ナラティブの更新 • May 15
BIO: Share Repurchases Will Support Future Upside Despite Lower Margin Outlook
Analysts have trimmed their price target on Bio-Rad Laboratories from $321.25 to $293.00, reflecting updated views on growth, margins, discount rate, and future P/E assumptions. What's in the News From January 1, 2026 to March 31, 2026, Bio-Rad Laboratories repurchased 176,257 shares for US$47.42 million, equal to 0.65% of its shares.ナラティブの更新 • Apr 29
BIO: Completed Buybacks And Intangible Impairment Will Support Future Upside
Analysts maintained their $320.00 price target for Bio-Rad Laboratories, making only minor adjustments to assumptions for discount rate, revenue, profit margin, and future P/E ratio to support this unchanged outlook. What's in the News Reported impairment charges of purchased intangibles and related items of $172.8 million for the fourth quarter ended December 31, 2025 (Key Developments).ナラティブの更新 • Apr 15
BIO: Buybacks And Intangible Impairment Will Shape Balanced Forward Expectations
Analysts have reset their price target on Bio-Rad Laboratories from $375 to $320, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43 million under the buyback program announced on July 20, 2023 (Key Developments).ナラティブの更新 • Mar 31
BIO: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Bio-Rad Laboratories from $348.00 to $321.25, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that result in a slightly more conservative valuation framework. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback that was announced on July 20, 2023 (Key Developments).ナラティブの更新 • Mar 17
BIO: Share Repurchases And Intangible Impairment Will Shape Future Upside
Analysts have maintained their $375.00 price target for Bio-Rad Laboratories, citing only minor adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E to reflect updated model inputs rather than a change in their overall view. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).ナラティブの更新 • Mar 03
BIO: Share Repurchases And Margin Outlook Will Support Future Upside
Analysts have maintained their price target for Bio-Rad Laboratories at $375, citing updated assumptions that include slightly higher revenue, improved profit margins, and a lower future P/E multiple, which together support the unchanged assessment of fair value. What's in the News From October 1, 2025 to December 31, 2025, Bio-Rad Laboratories reported no additional share repurchases, with 0 shares bought for $0, under its existing buyback program (Key Developments).ナラティブの更新 • Feb 17
BIO: Share Repurchases Will Support Future Upside Despite Impairment Charges
Analysts are keeping their price target for Bio-Rad Laboratories steady at $375, with updated assumptions that include a slightly higher discount rate, a higher revenue growth outlook, a lower profit margin, and a higher future P/E multiple to reflect their latest view of the risk and return profile. What's in the News Completed share repurchase of 2,614,132 shares, representing 9.26% of the company, for a total of US$715.43 million under the buyback announced on July 20, 2023 (Key Developments).ナラティブの更新 • Feb 03
BIO: Fair Outlook Will Balance Richer Margins Against Higher Required Returns
Analysts have lifted their price target on Bio-Rad Laboratories from US$265 to US$325, reflecting updated views on slightly different growth assumptions, a higher projected profit margin, and an adjusted future P/E multiple. Valuation Changes Fair Value: updated from US$265 to US$325, indicating a higher implied valuation level.Seeking Alpha • Jan 22
Bio-Rad Laboratories Still Hampered By Underwhelming Core Growth
Summary Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the latter's bioprocessing business is looking better of late. Management's guidance has been volatile, with 2025 core revenue growth targets fluctuating from 2.5% to near zero, then modestly rebounding. ddPCR is a bright spot, but broader revenue growth remains constrained; I see fair value at $338–$390, with rerating contingent on sustained growth. Read the full article on Seeking Alphaナラティブの更新 • Jan 20
BIO: Share Buybacks And Oncology Assay Partnership Will Drive Future Upside
Analysts have kept their price target for Bio-Rad Laboratories broadly steady at about US$375.00, reflecting only slight adjustments to modeled discount rate, revenue growth, profit margin, and future P/E assumptions in their updated views. What's in the News From July 1, 2025 to September 30, 2025, Bio-Rad repurchased 212,578 shares, about 0.79% of its shares, for US$52.83 million under its existing buyback program.分析記事 • Jan 06
Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Key Insights Bio-Rad Laboratories' estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Current...ナラティブの更新 • Jan 06
BIO: Share Buybacks And Oncology Partnership Will Support Future Upside
Analysts have lowered their price target on Bio-Rad Laboratories from US$437 to US$375, based on updated assumptions that combine more moderate revenue growth expectations with a slightly higher discount rate and a lower future P/E, partially offset by a higher projected profit margin. What's in the News Completed share repurchase of 2,614,132 shares, or 9.26% of the company, for a total of US$715.43m under the buyback announced on July 20, 2023 (Key Developments).ナラティブの更新 • Dec 14
BIO: Share Repurchase Will Drive Attractive Shareholder Returns Ahead
Narrative Update on Bio-Rad Laboratories Analysts have reaffirmed their conviction in Bio-Rad Laboratories, with the price target effectively unchanged at approximately 348 dollars. Modest tweaks to the discount rate, long-term revenue growth, profit margin, and future valuation assumptions largely offset one another in updated models.ナラティブの更新 • Nov 28
BIO: Share Repurchase and Expanded Partnership Will Shape Performance in Coming Quarters
Analysts have maintained their price target for Bio-Rad Laboratories at $348.00, noting only minor adjustments to revenue growth and profit margin expectations this quarter. What's in the News Bio-Rad Laboratories completed the repurchase of 2,614,132 shares, representing 9.26% of outstanding shares, for $715.43 million under a buyback program announced in July 2023.ナラティブの更新 • Nov 14
BIO: Share Repurchase and Expanded Partnerships Will Influence Future Performance
Analysts have raised their price target for Bio-Rad Laboratories from $324 to $348. They cite updated financial assumptions as well as small shifts in projected growth rates and profitability.ナラティブの更新 • Oct 30
BIO: Expanded Diagnostics Partnership Will Drive Margin Improvements Amid Mixed Revenue Outlook
Analysts have raised their price target for Bio-Rad Laboratories from $310 to $324, reflecting updated profit margin estimates. These changes more than offset slightly lower revenue growth expectations.ナラティブの更新 • Sep 28
Molecular Diagnostics Expansion Will Unlock Potential While Cost Challenges Persist
The decline in Bio-Rad Laboratories’ consensus price target to $310.00 primarily reflects lower future P/E and revenue growth expectations. What's in the News Completed buyback of 2,401,554 shares (8.47% of outstanding) for $662.6 million under program announced July 2023.分析記事 • Aug 03
Analysts Are Updating Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Estimates After Its Second-Quarter Results
Investors in Bio-Rad Laboratories, Inc. ( NYSE:BIO ) had a good week, as its shares rose 7.7% to close at US$285...分析記事 • Jul 14
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...新しいナラティブ • May 13
Acquisition And Droplet Digital PCR Will Advance Oncology Diagnostics
Bio-Rad's efforts in digital PCR technology and strategic acquisitions aim to expand applications and bolster revenue through oncology diagnostics and rare mutation detection.Seeking Alpha • Jan 29
Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential
Summary Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin leverage over the long term, and there are only a handful of meaningful revenue drivers with above-average potential. I believe BIO management has long been too conservative and unfocused with its R&D spending, but recent commentary suggests that growth potential and ROI will play a bigger role going forward. Bio-Rad's stake in Sartorius remains a significant store of value, but management's long-term plans remain unclear. While undervalued and having potential for longer-term growth upside, I remain cautious due to management and strategic concerns, as well as a large reliance on Sartorius to drive overall value. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
Why Bio-Rad Laboratories Is Overvalued: A Fundamental And DCF Analysis
Summary Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net sales are expected to decline in 2024. Valuing Bio-Rad using a discounted cash flow model indicates that the BIO stock is overvalued by 20.10%. Read the full article on Seeking AlphaSeeking Alpha • Sep 23
Bio-Rad Laboratories: Overvalued Given Current Growth Prospects
Summary Bio-Rad Laboratories is buying back a considerable amount of its own stock given the shares' current valuation and growth prospects. Profits and sales are expected to rebound in FY2025. A fuller look at Bio-Rad Laboratories is provided in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jul 14
Bio-Rad: Economics Unsupportive With Capital Valued 70 Cents On The Dollar
Summary Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research and clinical diagnostics products. The company's stock has been underperforming due to various pressures, including its position in Sartorius AG. Despite potential catalysts like product launches, the stock is considered overvalued with weak returns on capital and declining margins. Read the full article on Seeking AlphaSeeking Alpha • Apr 14
Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Summary Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the life sciences space have been challenging, driving, double-digit declines in Bio-Rad's Life Sciences segment, and neither biopharma nor academic/government budgets look great for 2024. Bio-Rad's holdings in Sartorius bring significant value to the company, but Sartorius shares have sold off considerably since the bioproduction bubble popped and investor enthusiasm has faded. There's an interesting some-of-the-parts story here, particularly if bioproduction growth resumes after a period of capacity digestion, but it's hard to love Bio-Rad on a standalone basis. Read the full article on Seeking Alpha株主還元
| BIO | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 0.5% | 2.1% | 1.6% |
| 1Y | 20.2% | 16.5% | 18.6% |
業界別リターン: BIO過去 1 年間で16.5 % の収益を上げたUS Life Sciences業界を上回りました。
リターン対市場: BIO過去 1 年間で18.6 % の収益を上げたUS市場を上回りました。
価格変動
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: BIO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BIOの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1952 | 7,450 | Norman Schwartz | www.bio-rad.com |
バイオ・ラッド・ラボラトリーズ・インクは、ライフサイエンス研究・臨床診断製品の開発、製造、販売を米国、欧州、アジア、カナダ、中南米、および国際的に行っている。ライフサイエンスと臨床診断の2つのセグメントで事業を展開している。ライフサイエンス部門は、細胞、タンパク質、核酸などの生物学的物質を分離、精製、特性評価、定量化するための装置、システム、試薬、消耗品を開発、製造、販売しており、研究・バイオ医薬品ラボ環境、バイオ医薬品製造、品質管理プロセス、食品安全、科学教育用途に使用されている。同事業は、大学や医学部、産業研究機関、政府機関、製薬メーカー、バイオテクノロジー企業、食品メーカー、試験所などにサービスを提供している。臨床診断部門は、臨床検査室、病院検査室、診断基準検査室、輸血検査室、医院検査室向けの診断検査システム、インフォマティクスシステム、検査キット、特殊品質管理、ソフトウェアの設計、製造、販売、サポートを行っている。同社は、直接の商業組織、および販売代理店、代理店、ブローカー、再販業者を通じて製品を提供している。バイオ・ラッド・ラボラトリーズ社は1952年に設立され、カリフォルニア州ハーキュリーズに本社を置いている。
Bio-Rad Laboratories, Inc. 基礎のまとめ
| BIO 基礎統計学 | |
|---|---|
| 時価総額 | US$7.94b |
| 収益（TTM） | US$168.80m |
| 売上高(TTM) | US$2.59b |
47.1x
PER（株価収益率3.1x
P/SレシオBIO は割高か？
公正価値と評価分析を参照収益と収入
| BIO 損益計算書（TTM） | |
|---|---|
| 収益 | US$2.59b |
| 売上原価 | US$1.24b |
| 売上総利益 | US$1.35b |
| その他の費用 | US$1.18b |
| 収益 | US$168.80m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 6.31 |
| グロス・マージン | 52.01% |
| 純利益率 | 6.52% |
| 有利子負債／自己資本比率 | 17.4% |
BIO の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/06 06:03 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Bio-Rad Laboratories, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19
| アナリスト | 機関 |
|---|---|
| Jon Wood | BofA Global Research |
| Yuan Zhi | B. Riley Securities, Inc. |
| Patrick Donnelly | Citigroup Inc |